N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma

Oncotarget
Yoshiaki AbeKosei Matsue

Abstract

We retrospectively explored the prognostic relevance of N-terminal pro-brain natriuretic peptide (NT-proBNP) and the association of NT-proBNP with cardiac and renal functions in 153 patients with newly diagnosed symptomatic multiple myeloma and no concomitant light chain amyloidosis who received novel agents. We also examined the usefulness of the new frailty system recently introduced by Mayo Clinic (combining age, performance status, and NT-proBNP). Patients with higher NT-proBNP levels (≥300 ng/L) had a significantly higher incidence of left ventricular diastolic dysfunction (LVDD) and myeloma-related renal insufficiency and significantly shorter overall survival (OS) than did those with lower NT-proBNP levels (<300 ng/L). NT-proBNP remained predictive of OS on multivariate analysis. Mayo Clinic's new frailty system showed excellent discrimination of OS. Furthermore, the Instrumental Activity of Daily Living (IADL) score (not evaluated in Mayo Clinic's study) predicted OS independently of this system, and a sharper discrimination of OS curves was obtained by the incorporation of IADL into this system. Our findings demonstrated that NT-proBNP levels were associated with both LVDD (as a host risk factor) and myeloma-related re...Continue Reading

References

May 15, 1997·Statistics in Medicine·D W HosmerS Lemeshow
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Feb 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz LudwigBrian Durie
Jan 5, 2011·Statistics in Medicine·Michael J PencinaEwout W Steyerberg
May 4, 2011·Clinical Cardiology·Victor FelizMaya Guglin
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaji KumarMorie A Gertz
Feb 1, 2013·The New England Journal of Medicine·Monte S Willis, Cam Patterson
Dec 3, 2013·Journal of the American College of Cardiology·Siu-Hin WanHorng H Chen
Dec 3, 2014·The Lancet Oncology·S Vincent RajkumarJesus F San Miguel
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboPhilippe Moreau
Apr 3, 2016·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Sherif F NaguehAlan D Waggoner
Jul 5, 2017·European Journal of Haematology·Flora ZagouriUNKNOWN Greek Myeloma Study Group
Jul 21, 2017·Nature Reviews. Disease Primers·Shaji K KumarKenneth C Anderson
Dec 15, 2018·Journal of the American Geriatrics Society·Tanya M WildesGraham Colditz

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies

Software Mentioned

R
STATA

Related Concepts

Related Feeds

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.